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Abstract 28 
Hypoxia upregulates hypothalamic corticotrophin releasing hormone (CRH) and its receptor type-1 (CRHR1) 29 
expression and activates the HPA axis and induces hypoxic sickness and behavioral change. The transcriptional 30 
mechanism by which hypoxia differently regulates CRHR1 expression remains unclear. Here we report hypoxia 31 
time-dependently induced biphasic expression of CRHR1mRNA in rat pituitary during different physiological status. 32 
Short exposure of gestational dams to hypoxia reduced CRHR1mRNA in the pituitary of P1-P14 male rat offspring. 33 
A short- and prolonged-hypoxia evoked biphasic response of CRHR1mRNA characterized initially by decreases and 34 
subsequently by persistent increases, mediated by a rapid negative feedback via CRHR1 signaling and positive 35 
transcriptional control via NF-κB, respectively. Further analysis of CRHR1 promoter in cultured primary anterior 36 
pituitary and AtT20 cells showed that c-Jun/AP-1 delivered negative while HIF-1α and NF-κB delivered positive 37 
control of transcription at CRHR1 promoter. The negative and positive inputs are integrated by hypoxic initiation 38 
and duration in CRHR1 transcription.   39 
 40 
Keywords: AP-1; CRH; Corticotropin-releasing hormone receptor 1;Hypoxia;NF-κB;Transcription; 41 
 42 
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1. Introduction 44 
CRH and CRHR1 are well known to play a crucial role in homeostasis, endocrine and behavior modulation (Ramot 45 
et al., 2017; Hillhouse and Grammatopoulos, 2006; Carlin et al.,2006; Refojo et al.,2011; Nikodemova et al., 2002; 46 
Westphal etal., 2009; Klenerova et al., 2008; Potter et al., 1994; Kolasa et al., 2014) by coordinating the response of 47 
the brain and the HPA axis during stresses, including hypoxia (Chen et al., 2012; Fan et al., 2009; Wang et al., 2013; 48 
Wang et al., 2004; Xu et al., 2006). Hypoxia is a common pathophysiological event with a potential influence on 49 
gene transcription. Hypoxia stimulation of the HPA axis may be experienced by embryos in utero, neonates, adults, 50 
and elders, showing a distinct spatio-temporal change in CRHR1 mRNA expression. We have previously reported 51 
that exposure of neonatal rats to hypoxia activates CRH and CRHR1 mRNA expression and the HPA axis, and 52 
gestational hypoxia induces an anxiety-like behavior and down-regulates the methylation of CRHR1 promoter but 53 
upregulates CRHR1 mRNA in the hypothalamus paraventricular nucleus (PVN) of male offspring (Fan et al., 2009; 54 
Fan et al., 2013; Wang et al., 2013). In regard to the HPA axis, hypoxia can downregulate or upregulate CRHR1 55 
mRNA expression in rat anterior pituitary (Wang et al., 2004; Xu et al.,2006), but the precise mechanisms 56 
underlying the transcriptional modulation are not as yet assessed. Increasing numbers of publications suggest that 57 
hypoxia-activated or depressed gene expressions are implicated in many physiological and pathological processes. 58 
Hypoxia exerts profound effects on the transcription of a large number of genes across a wide range of oxygen 59 
tensions (Chen et al., 2012; Chen et al., 2014; Semenza, 2009; Rocha, 2007; Cummins and Taylor, 2005; Seta and 60 
Millhorn, 2004; Bruning et al., 2012), including hypoxia-inducible factor (HIF-1), a major transcription factor in 61 
controlling the ubiquitous transcriptional response to hypoxia, CREB, a c-AMP response element bind protein, 62 
nuclear factor-κB (NF-κB), and activator protein-1 (AP-1) (Semenza, 2009; Cummins and Taylor, 2005; Bruning et 63 
al., 2012). NF-κB is a family of five proteins including RelA (p65), RelB, c-Rel, NF-κB1 (p105/p50), and NF-κB2 64 
(p100/p52) that are ubiquitously expressed, form homo- or heterodimers and act as a transcriptional mediators of 65 
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gene in response to numerous stimuli (O'Dea and Hoffmann, 2010; Hoffmann et al., 2006). Significantly, the 66 
modulation of hypoxia-sensitive genes by NF-κB is commonly complemented by AP-1, a dimeric immediate-early 67 
transcription factor that is an important pleiotropic facilitator of transcriptional cascades (Cummins and Taylor, 68 
2005).  69 
Whilst these data are suggestive of the possible molecular mechanisms involved in controlling hypoxia-induced 70 
CRHR1 gene expression in the pituitary, details of transcription and the molecular pathways have not been 71 
elucidated. Since the extent to which hypobaric hypoxia influences gene expression may depend on the time period 72 
of exposure and also on the stage of an animal’s development we studied CRHR1 transcription in four hypoxia 73 
models with different physiological status: a) a short exposure of gestational dams to hypoxia (SGH) where dams 74 
were exposed to simulated altitude of 5000 m for 4 h per day; b) a short period hypoxia (SH) where the adult rats 75 
were exposed  to simulated altitude of 7000 m for 1, 8 and 24 h; c) a prolonged hypoxia (PH) where adult rats were 76 
exposed to simulated altitude of 5000 m for 2 and 5 days. Finally d) we established an in vitro cell culture model to 77 
study the hypoxia induced cellular mechanisms of transcriptional control involved in the promoter of CRHR1. We 78 
found that hypoxia distinctly induced a bidirectional (biphasic), initially down, followed by up expression of 79 
CRHR1 mRNA in rat pituitary cells that was transcriptionally controlled negatively by corticosterone (Corts) and 80 
Jun/AP-1, and positively by NF-κB, and HIF-1α signaling input. 81 
 82 
2. Materials and methods 83 
2.1. Animals 84 
Virgin female, Sprague-Dawley rats weighing 220 ± 20 g were purchased from the Experimental Animal Center 85 
of Zhejiang Province (Hangzhou, Zhejiang, China; License No. SCXK2008-0033; SCXK (Shanghai) 2012-0002). 86 
Groups of three female rats were housed overnight with one eugamic male weighing 350 ± 20 g. The day on which 87 
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sperm was microscopically observed in vaginal smears was designated as embryonic day 0 (E0). The pregnant rats 88 
were randomly allocated to gestational dams to hypoxia (SGH) and control groups. Rats were housed individually 89 
under a 12-h light/dark cycle (lights on at 06:00) in a temperature-controlled room at 22 ± 2°C. Food and water were 90 
provided ad libitum and the cages were cleaned twice weekly. All experiments were conducted accordance with the 91 
NIH laboratory animal care guidelines. All protocols concerning animal use were approved by the Institutional 92 
Animal Care and Use Committee of School of Medicine, Zhejiang University (ZJU201304-1-01-025). 93 
 94 
2.2. Prenatal hypoxia stress 95 
A short exposure of SGH. Dams in the SGH group were placed into a hypobaric chamber (Avic Guizhou Fenglei 96 
Aviation Armament Co., Ltd, China, FLYDWC-50-IIC) simulating hypoxia at 5000 m altitude (equivalent to 97 
~10.8% O2 at sea level) for 4 h/day throughout pregnancy period (E1-E21). The treatment was imposed once daily 98 
from 08:00 to 12:00 (Fig.1) (Fan et al., 2009; Fan et al., 2013; Wang et al., 2013). The dams in the control group 99 
were kept in the same chamber at sea level (equivalent to ~ 21 % O2) under the same conditions as the SGH group. 100 
At the end of SGH experiment, the neonatal babies (litter) were kept with own mother until test. The day of the 101 
litter’s birth was considered as postnatal day 0 (P0). After birth, the pups were left undisturbed with their biological 102 
mothers until weaning at P21. They were randomly distributed according to birth day (P1, P7, P14, P21 and P90) 103 
and housed in groups of five or six per cage (Wang et al., 2013). The brains and pituitary of 8 of these post natal 104 
offspring were studied without further exposure to hypoxia tests and to minimize intra-specific differences, no more 105 
than two male rats from each litter were used for a further test of CRHR1 methylation and mRNA expression in 106 
brain and pituitary. 107 
 108 
2.3. Adult hypoxia stress 109 
A short period hypoxia (SH). Healthy adult male Sprague-Dawley rats (Experimental Animal Center, Zhejiang, 110 
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China) weighing 180 ± 20 g were group-housed in the behavior lab 7 days for environmental adaptation before 111 
experiments. Rats in the hypoxia group were placed in a hypobaric chamber and exposed to hypobaric hypoxia of 112 
7000 m altitude (~8.2% O2)for 1, 8, 24 h (Fig. 2A, B,C,F,G,H,J) or a prolonged hypoxia (PH), which mimicked at   113 
altitude of 5000 m  (~10.8% O2 ) for 2 or 5 days (4 h/per day, Fig.2D,E,I)(Hao et al., 2015). The normoxia group 114 
(Control, Con) was placed in the same chamber set at sea level (~ 21 % O2). Rats were randomized into different 115 
groups. 1. The Control group was injected (ip) with 0.9% saline. 2. The Hypoxia group was injected with vehicle 116 
(0.9% saline) before hypoxia stress. 3. Dex group was injected with Dexamethasone (Dex, 500 µg/kg, ip) for 2 days 117 
(4 h hypoxia /day, Fig.2I). 4. PDTC group was injected with PDTC (The pyrrolidine dithiocarbamate, an inhibitor of 118 
NF-κB, 150 mg/kg, Chen, et al., 2013) for 5 days (4 h hypoxia (10.8% O2) /day, Fig.2E) or for 8 h hypoxia (8.2% 119 
O2, Fig.2B,G). 5. An antagonist group (Fig.2C,H) was treated with CP154,526 (an antagonist of CRHR1, 30 mg/kg, 120 
kindly donated by Pfizer Inc.USA). After exposure, rats were rapidly decapitated within half an hour at 14:00 -14:30 121 
to minimize circadian rhythm effects.  122 
 123 
2.4. Sample collection   124 
At E12 and E19, dams were anesthetized with intraperitoneal injection of sodium pentobarbital (30 mg/kg) after 125 
SGH and sacrificed by decapitation. In the fetuses, the anogenital distance was measured, the sex was determined, 126 
and the brain (E12) or hypothalamus (E19) was snap-frozen in liquid nitrogen and stored -80 oC until DNA and 127 
RNA isolation.  128 
   The offspring (P1, P7, P14, P21, and P90) were sacrificed by decapitation, and the pituitary was removed, snap-129 
frozen in liquid nitrogen and stored -80 oC until DNA and RNA isolation. The adult rats were also sacrificed by 130 
decapitation after exposure to hypoxia stress, and the pituitary was snap-frozen in liquid nitrogen and stored -80 oC, 131 
the trunk blood were collected (in EDTA tube), plasma was obtained by centrifugation and stored at -80°C.  132 
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Plasma corticosterone (Cayman Chemical) was estimated with commercial ELISA kits for rats. The sensitivity 133 
of the assay was 0.40 ng/mL, and interassay and intraassay coefficients of variation were 6.5% and 4.5%, 134 
respectively. The antibody cross-reacted 100% with corticosterone and <0.5% with other steroids.   135 
 136 
2.5. Real-time qPCR and DNA methylation analysis of the CRHR1 promoter 137 
Total RNA was reverse-transcribed to cDNA using TransScriptTM First-Strand cDNA Synthesis SuperMix 138 
(TransGen Biotech, Beijing, China). Changes in human CRHR1 (NM_001145146.1) and rat CRH (NM_031019.1), 139 
CRHR1 (NM_030999.3), were assessed using SYBR Premix Ex TaqTM (TaKaRa Biotechnology Co., Ltd., Dalian, 140 
China). In addition, rat 18S ribosomal RNA was amplified for each sample as an endogenous control, and the cycle 141 
threshold was subtracted from the target threshold value. All samples and negative controls were prepared in 142 
duplicate wells of a 384-well plate and analyzed using the PRISM7900HT real-time PCR system (Applied 143 
Biosystems, Foster City, CA, USA). The cycle number at threshold (CT value) was used to calculate the relative 144 
amount of mRNA. The CT value of each target was normalized by subtraction of the CT value of 18 s. Primers were 145 
used in qPCR are shown in the supplementary material (Table S1).  146 
Transcription factor binding sites were predicted using the MATCH software (http://www.gene-147 
regulation.com/cgi-bin/pub/programs/match/bin/match.cgi) and http://jaspar.genereg.net/, with cut-off selection for 148 
matrix to minimize the false negatives (Supplementary Fig. 1 and Fig. 2 for transcription factor binding sites of 149 
mouse and rat in the region of the CRHR1 promoter). CpG island status within the promoter region of CRHR1 150 
(NC_005109.2) and bisulfite DNA sequencing PCR (BSP) primer were both analyzed using MethPrimer-Design 151 
Primers for Methylation PCRs (http://www.urogene.org/methprimer/index1. html) (Wang et al., 2013; Li and Dahiya, 152 
2002). DNA was isolated from the E12 brain and hypothalamus of E19 embryos and pituitary in offspring. Genomic 153 
DNA (500 ng) was bisulfite-converted using the EZ-DNA Methylation-Gold KitTM (Zymo Research Corp., CA, 154 
USA) according to the manufacturer’s instructions. Bisulfite treatment of genomic DNA converts cytosine to uracil, 155 
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but leaves methylated 5’ cytosine unchanged. The BSP primer pairs used for the assessment of the CRHR1 CpG 156 
islands (106 bp) were shown in the supplementary material (Table S1).  157 
The BSP products were sequenced using the forward primer by Genscript Biotechnology Co. (Nanjing, China), 158 
two samples for each E12 brain and pituitary was sequenced. The first CpG island between -609 and -502bp 159 
functions is the major regulatory domain of CRHR1 transcription activity (Wang et al., 2013), methylation of each 160 
CpG site within the region were tested. The percentage methylation of each CpG site within the region amplified 161 
was determined by the ratio between the peak values of C and T (C/[C+T]), and these levels were determined using 162 
Chromas software 2.31. 163 
 164 
2.6. Plasmid construction and site-directed mutagenesis 165 
Genomic DNA was isolated from the anterior pituitary of male Sprague Dawley rats, and used as a template to 166 
amplify the 5’-flanking region of the CRHR1 gene ranging from -2161 to +347 by using a primer set 167 
(supplementary Table S1). Primers were designed based on Rattus norvegicus genome data resources 168 
(NW_047340.1, Rn10_WGA1860_4:1983790-1984316). The amplified PCR product was subcloned into pMD18-T 169 
vector (Takara) and sequenced, The PCR fragment was isolated again by digesting of XhoI and HindIII, and then 170 
subcloned into a promoter less luciferase vector (pGL3-basic; Promega) in the sense orientation to generate 171 
p2161Luc. A series of truncated pGL3-basic plasmids containing the 5’-flanking region of the rat CRHR1 gene (-172 
2161/+347, -1833/+347, -1795/+347, -1692/+347, -1289/+347, -1248/+347, -1218/+347, -1140/+347, -838/+347, -173 
687/+347 and -360/+347) were constructed in the similar manner. Two sets of mutants with the NF-κB site 174 
positioned at -809~-800 (p838) mutation and c-Jun(AP-1) mutation were constructed by site-directed mutagenesis to 175 
create Mutated Luc using primers (supplementary Table S1). The full open reading frame of rat c-Jun gene was 176 
amplified by PCR from rat cDNA based on published sequence (1,005 bp; NM_021835.3) by using forward primer 177 
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(supplementary Table S1). pcDNA3.1-c-Jun was generated by inserting the PCR fragment into the pcDNA3.1 vector 178 
(Invitrogen) and sequencing. 179 
 180 
2.7. Cell culture and transfection and Cell treatment 181 
We established an in vitro cell culture models. AtT20[mouse pituitary tumor cells AtT20, American Type 182 
Culture Collection (ATCC) CCL-89™]cell lines were grown in RPMI medium 1640 (Gibco) or DMEM (Gibco), 183 
respectively, containing 10% (vol/vol) FBS, and 100 U/ml penicillin at 37 °C in a humidified incubator with 5% 184 
(vol/vol) CO2. AtT20 cells were plated into 12-well plates with approximately 80% confluence. Two days after 185 
plating, cells were transiently transfected with 1 µg reporter construct using the Lipofectamine 2000 reagent 186 
(Invitrogen) according to the manufacturer’s instructions. For cotransfection experiments, 1 µg reporter plasmid was 187 
cotransfected with 1 µg pcDNA 3.1-c-Jun/AP-1 or the empty pcDNA 3.1 vector. All analyses were performed 24-48 188 
h after transfection.  189 
For primary pituitary cell (RPC) culture, the anterior pituitary glands from male Sprague Dawley rats (male, 180-190 
200 g) were quickly removed, and then chopped into little pieces (about 1×1 mm) with a small dissecting scissor, 191 
and dispersed by incubation with 1 mg/ml trypsin (Sigma, Madrid, Spain) in Hank’s balanced salt solution (Life 192 
Technologies, Inc., Paisley, UK) at 37°C for 15 min. The primary anterior pituitary cells were cultured in DMEM 193 
containing 100 U/ml penicillin G potassium, 1 mg/ml streptomycin sulfate and 10% FBS. The cells were maintained 194 
in a humidified incubator at 37 °C in 5% CO2 and 95% air for 7 days, and used for the following experiments. 5×106 195 
primary anterior pituitary cells were nucleofected (Nucleofector, Amaxa Biosystems GmbH, Cologne, Germany) in 196 
an electroporation cuvette along with nucleofector solution R and 2 µg plasmids using the programme A-023. Cells 197 
were transferred into fresh pre-warmed media with 10% FBS and incubated for 24 h. Dual-luciferase reporter assays 198 
were performed using a dual-luciferase reporter assay system (Promega Corp., WI, USA).  199 
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The hypoxia treatment was performed using the Proox Model P110 and ProCO2 Model P120 hypoxia systems 200 
(BioSpherix, USA). AtT20 and RPC were moved to the hypoxia incubator in which the oxygen level was set as 201 
indicated (1% O2 hypoxia chamber with 1% O2, 5 % CO2, and 94% N2) or normoxia condition (21%O2) (Zhang et 202 
al., 2016; Zhao et al., 2013; Zhang et al., 2013). AtT20 cells were treated with CRH(10 nM, Tocris Bioscience), 203 
PDTC (10 or 100 µM), antibody (NF-κB or AP-1) , or AP-1 inhibitor ( SR11302,1 or 10 µM, Tocris Bioscience ) 204 
for 24 h.  205 
 206 
2.8 Electrophoretic mobility shift assays (EMSA) and Western blot 207 
EMSAs were done to illustrate the activation of AP-1 or NF-κB in rat pituitary or cultured AtT20 cells under 208 
hypoxia condition. The nuclear extracts from the rat pituitary or cultured AtT20 cells were prepared with NE-PER 209 
Nuclear and Cytoplasmic Extraction reagents (Pierce Biotechnology, USA), according to the manufacturer’s 210 
protocol. The protein concentration of the nuclear extract was quantitated using the Bradford protein assay. 211 
Oligonucleotides probe were 3’-end-biotinylated (50 fmol) encompassing the NF-κB binding sequence 212 
(supplementary Table S1). The probe with sequences (CGGAGACTCC or TGAGTCA) specifically binds NF-κB or 213 
AP-1 respectively. The probes were synthesized by company (Takara Biotechnology Co., Ltd., Dalian, China). Non 214 
relative antibody (NA) and non relative competitor (NN) for experimental control, antibody of NF-κB (anti-p65/p50, 215 
sc -372, dilution 1:1000, Santa Cruz, USA), c-Jun antibody p-c-Jun (Ser 63/73): sc-16312, dilution 1:1000, Santa 216 
Cruz, USA) were used. Western blot was performed to determine the protein level of CRHR1 in tissue, monoclonal 217 
antibody against CRHR1(48 KD, R&D systems), GAPDH(36 KD, 1:1000, Abcom) were used. Lysed samples were 218 
centrifuged (14,000x g for 15 min) at 4 oC, and boiled with 6 x loading buffer at 95 oC for 5 min. After 219 
electrophoresis, proteins were transferred to PVDF membrane and incubated antibodies. 220 
 221 
2.9 Chromatin Immunoprecipitation (ChIP) Assay  222 
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The chromatin immunoprecipitation (ChIP) assay was performed using ChIP kit according to the manufacturers’ 223 
instructions (EZ ChIPTM-Catalog # 17-371, Millipore, USA). AtT-20 cells were seeded in 60-mm dishes, after 224 
treatment for 24 h, AtT-20 cells were fixed with 1% formaldehyde at room temperature for 10 minutes and 225 
terminated with glycine. The fixed cells were harvested with ice-cold PBS containing Protease Inhibitor Cocktail II, 226 
and the pellet was resuspended in SDS lysis buffer. Then, the DNA was sheared to 200- to 1000-bp fragments by 227 
sonication. Immunoprecipitation was performed using c-Jun antibody (1:50, Cell Signaling) or NF-κB p65 antibody 228 
(1:100, Cell Signaling) with rotation overnight at 4oC. Protein/DNA complexes were captured in elution buffer, and 229 
cross-links were reversed to free DNA. After DNA purification, normal PCR and quantitative PCR was performed 230 
using CRHR1 promoter-specific primers and the binding sites (Supplementary S Table 2 and 3). 231 
 232 
3.0. Statistical analysis 233 
All studies were conducted by an investigator blind to SGH groups. For CRHR1 gene methylation in embryos and 234 
offspring pituitary, that data were analyzed using two-tailed unpaired t tests. For Effect of CRH, PDTC, and AP-1 235 
on CRHR1 mRNA in vitro were analyzed by using one-way ANOVA. Post hoc comparisons after one-way 236 
ANOVA were made using Tukey’s post hoc test (GraphPad Prism6). All data are presented as mean ± SD. P<0.05 237 
was considered statistically significant. 238 
 239 
3. Results 240 
3.1. CRHR1 expression and CRHR1 methylation in embryos brain and P1-P90 pituitary after short exposure of 241 
gestational dams to hypoxia 242 
 243 
To determine whether gestational short period hypoxia alters CRHR1 promoter methylation, and thereby changes 244 
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CRHR1 mRNA, CRHR1 mRNA and CRHR1 promoter methylation were measured. CRHR1 mRNA and CRHR1 245 
promoter methylation was not significantly changed in the CpG island 1 of the promoter in the E12 brain 246 
(Supplementary Fig. 3A and B). We next investigated the effect of SGH on CRHR1 mRNA expression and 247 
methylation of the CRHR1 gene promoter in the pituitary of postnatal male offspring who had not been subjected to 248 
a further hypoxia test. CRHR1 mRNA levels were markedly decreased in P1, P7 and P14 offspring (Fig.1A), 249 
however on day P21, both control and SGH animals the CRHR1 mRNA levels were dramatically increased to a 250 
similar extent in each. DNA methylation levels were markedly reduced at sites -547,-544, -535 within the CRHR1 251 
CpG promoter in P1 males (p<0.05; Fig. 1B), but no significant differences in methylation within the CRHR1 252 
promoter CpG island 1 were found at P7, P14 or P21 (Fig. 1B). On day P90, there was no significant difference 253 
from control and SGH rats in the CRHR1 mRNA levels and CRHR1 DNA methylation levels in pituitary (Fig. 254 
1C,D). These data indicate that there is no logical association between CRHR1 mRNA and CRHR1 DNA 255 
methylation in postnatal offspring following exposure to gestational hypoxia. 256 
 257 
3.2. Hypoxia-induced bidirectional expression and regulation of CRHR1 mRNA in rat pituitary  258 
 259 
Short periods of 1 h and 8 h hypoxia (SH, at altitude of 7000 m) reduced CRHR1 mRNA whereas prolonged 260 
hypoxia (PH) of 2 d or 5 d at altitude of 5000 m (4 h hypoxia/day) increased CRHR1 mRNA in adult male rat 261 
pituitary (Fig. 2A, B), thus showing a spatio-temporal bidirectional (biphasic) response pattern of CRHR1 262 
expression. To further explore the regulatory and transcriptional mechanism underlying the bidirectional response of 263 
CRHR1 under the similar hypoxia, SH and PH condition, the adult rats were treated with hypoxia and with or 264 
without pretreatment of PDTC (a NF-κB inhibitor), CP154,526 (a CRHR1 antagonist), or Dex (glucocorticoid 265 
hormone and suppressant of CRH), respectively (Fig. 2C,D,E, and I). The hypoxia 8 h-reduced pituitary CRHR1 266 
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mRNA levels, were markedly reversed by pretreatment of CP154,526, an antagonist of CRHR1(Fig. 2D), but not by 267 
PDTC, a inhibitor of NF-κB (Fig. 2C), indicative of a role for glucocorticoid negative feedback in the initial phase 268 
of CRHR1 suppression during short hypoxia. By contrast, prolonged hypoxia (PH) for 5 or 2 days-increased 269 
CRHR1 mRNA expression, was reversed by pretreatment of PDTC, but not by Dex, indicative of a role for NF-κB 270 
(Fig. 2E) and ruling out a role for glucocorticoid negative feedback (Fig. 2I). Furthermore, CRH mRNA expression 271 
increased markedly at 2, 8, and 24 h of acute short hypoxia (SH), reaching a peak at 8 h (Fig. 2F), and was blocked 272 
by pretreatment of PDTC (Fig. 2G) or CP154,526 (Fig. 2H). This raised the possibility that both NF-κB and CRHR1 273 
signaling may contribute to local regulation of the rapid increase in CRH mRNA expression in adult rat pituitary 274 
cells. However, plasma Corts levels were increased during acute hypoxia at 2, 8, and 24 h and in a time-dependent 275 
manner (Fig. 2J), indicating fast negative feedback suppression to CRHR1 gene expression by Corts during short 276 
hypoxia. Moreover, EMSA test showed hypoxia increased p65 or p50 protein binding with nuclear protein, and this 277 
binding could be blocked by PDTC and Mut NF-κB (Fig. 2K, L). Consideration of these findings as a whole (Fig. 2) 278 
reveals that hypoxia delivers bidirectional control of CRHR1 expression, characterized by initially fast suppression 279 
by Corts then sustained increase of CRHR1 expression by NF-κB transcription. 280 
 281 
3.3. Hypoxia increased CRHR1 promoter activity in primary rat pituitary cell and AtT20 cell 282 
 283 
To address CRHR1 gene transcriptional mechanisms in pituitary cells under hypoxia, the p2161Luc plasmid 284 
containing the length of CRHR1 gene promoter region (-2161) was constructed and transfected into primary rat 285 
pituitary cell (RPC) cells or AtT20 cells, and dual-luciferase activity assay was performed to test the CRHR1 286 
promoter activity. Hypoxia (1% O2) caused a significant increase in promoter activity of the reporter gene in RPC 287 
cells (1.5-fold; p<0.05; Fig.3A) and AtT20 cells (2.5-fold; p<0.05; Fig. 3B), compared with normoxia (21% O2). An 288 
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empty vector (pGL3-basic) was transfected as a control to adjust the contribution of the ligated region. Hypoxia 289 
significantly increased rat CRHR1 gene transcription in a time-dependent manner within 4-24 h of hypoxia exposure 290 
(*p<0.05, ***p<0.001, Fig. 3C). 291 
 292 
3.4. HIF-1α, NF-κB, and AP-1 involvement in transcription of CRHR1 promoter during hypoxia 293 
 294 
Bioinformatics analysis predicts that there are four NF-κB, five Jun/AP-1, eight HIF-1α binding sites, and one 295 
HAS (HIF-1 ancillary sequence) in the 5’ flanking region of rat CRHR1 gene, between -2161 and +360 (Fig. 4A). 296 
To distinguish whether these cis-elements are responsible for hypoxia-induced CRHR1 promoter activation and the 297 
different roles played in transcriptional activity by them, a series of deletion constructs for the CRHR1 promoter 298 
(from -p2161Luc to -p360Luc through deletion of transcriptional sites selected) were generated according to the 299 
distribution of these cis-elements. Transcriptional activity of all the constructs of CRHR1 promoter from p2161Luc 300 
to p838Luc were increased during hypoxia (1% O2) when compared to normoxia (p<0.001 and 0.05). However, 301 
transcriptional activity of p1218Luc was dramatically increased compared with p2161Luc, after deletion of the 302 
adjacent three AP-1 binding sites (triangle) (Fig. 4B, +++p<0.001), while transcriptional activity of p1218Luc was 303 
dramatically decreased relative to that of p838Luc following deletion of the adjacent HIF-1α binding sites (Fig. 4B, 304 
+++p<0.001). Deletion of NF-κB bindings sites (square) from p838Luc resulted in loss of transcriptional activity in 305 
p687Luc (p>0.05), and the shortest p360Luc failed to activate the transcription of reporter gene (Fig. 4B). 306 
Investigations on AtT20 cells in-vitro showed that transcriptional activities of p2161Luc, p1289Luc, and p838Luc 307 
increased in a time-dependent manner (4-24 h) under normoxia and hypoxia, but the rate of increase in 308 
transcriptional activities was significantly higher during hypoxia when compared with normoxia (Fig. 4C). 309 
 310 
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3.5. AP-1involvment in transcriptional suppression of CRHR1 gene under hypoxia and normoxia   311 
To determine whether AP-1 exerted a positive or negative influence on transcriptional activity of the Crhr1 312 
promoter p2161Luc to p1218Luc, we measured the transcriptional activity of p2161 Luc (the full length, including 313 
three AP-1 sites), p1218Luc (deleted the three of AP-1, but all HIF-1α contained), and p838Luc (deleted three HIF-314 
1α, but one NF-κB contained) in cultured AtT20 cells under both hypoxia (1% O2) and normoxia (21% O2). We 315 
found that deletion of the adjacent three AP-1 bindings sites (from p2161Luc shortened to p1218Luc) resulted in 316 
dramatically increased transcription, which strongly suggests that AP-1 exerts an inhibitory influence on expression. 317 
However, deletion of the adjacent three HIF-1α bindings sites (p1218Luc shortened to p838Luc) resulted in 318 
dramatic decreases in transcription, indicative of a positive influence on CRHR1 transcription (Fig. 5A),  ###p<0.001 319 
and +++p<0.001, compared under normoxia and hypoxia, respectively. Furthermore, using cultured AtT20 cells, 320 
CRHR1 mRNA level was measured in the presence and absence of CRH (10 nM) or an AP-1 inhibitor (SR11302, 10 321 
µM) in the culture media under normoxia (21% O2) or hypoxia (1% O2). CRH decreased CRHR1 mRNA levels and 322 
this decrease was reversed by the AP-1 inhibitor under normoxia, **p<0.01, ++p<0.01 (Fig. 5B). However, 1% O2 323 
increased CRHR1 mRNA and CRH induced a further increase which remained unaffected in the presence of the AP-324 
1 inhibitor, ##p<0.01, @@p<0.01 (Fig. 5B). EMSA experiments identified AP-1 binding under normoxia (lane 2 and 4) 325 
and relative increases AP-1 binding during hypoxia (lane 1 and 3). Mutated AP-1 resulted in loss of AP-1 binding 326 
(lane 5). An unlabeled probe, AP-1 competitor was used (Lane 6). Addition of a Jun/AP-1 antibody (lane 7) 327 
eliminated AP-1 binding. An uncorrelated antibody (NA, lane 8) had no such effect (Fig. 5C). These results indicate 328 
that hypoxia induces increases of Jun/AP-1 binding relative to normoxia, and that AP-1 inhibits transcriptional by 329 
binding to the CRHR1 promoter at sites p2161-p1289 and also AP-1 is responsible for CRH-induced reductions in 330 
CRHR1mRNA expression under normoxia. Under hypoxia, however, the inhibitory influence of AP-1 appears to be 331 
overcome by transcription activation through HIF-1α and NF-κB. 332 
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 333 
3.6. NF-κB involvement in hypoxia-activated CRHR1 promoter transcription  334 
 335 
To determine whether or not the NF-κB binding site (CGGAGACTCC) positioned at p838 within the CRHR1 336 
promoter is responsible for the increased CRHR1 promoter activity during hypoxia (1% O2, 24 h), we assessed the 337 
relative luciferase activity in cultured AtT20 cells with or without 10 µM PDTC. We found that hypoxia increased 338 
transcriptional activity of p838Luc CRHR1 promoter, and this effect was abolished by pretreatment with PDTC. 339 
Moreover mutation of p838Luc (Mut-p838) blocked the increases in transcription via the CRHR1promoter during 340 
hypoxia (p<0.01, Fig. 6A, B). Moreover, CRH (10 nM) decreased CRHR1 mRNA in cultured AtT20 cells under 341 
normoxia (21% O2)(**p<0.01), and this effect was not reversed by incubation with PDTC (NF-κB inhibitor, 10 µM; 342 
++p<0.01, Fig. 6C). However, hypoxia (1% O2) alone increased CRHR1 mRNA expression when compared to 343 
normoxia (***p<0.001), and CRH (10 nM) + hypoxia further increased CRHR1 mRNA expression (##p<0.01). This 344 
latter effect was blocked by co-incubation of cells with CRH (10 nM) and PDTC (NF-κB inhibitor, 10 µM; 345 
@@p<0.01, Fig. 6C), which suggests that CRH suppresses CRHR1 mRNA expression by AP-1-dependent inhibition 346 
of transcription during normoxia and in a manner that is overcome by increased expression driven by HIF-1α and 347 
NF-κB during hypoxia. EMSA experiments showed p65/p50 binding to nuclear protein under hypoxia in AtT20 348 
(lane 4, Fig. 6D). An excess amount (100-fold) of unlabeled probe (NF-κB competitor) resulted in loss of hypoxia-349 
induced p65 binding (lane 5, Fig. 6D). Mutated NF-κB also resulted in loss of hypoxia-induced p65 binding (lane 6, 350 
Fig. 6d) and p65/p50 antibody abolished the binding (lane 7, Fig. 6D), while non relative antibody (NA) was unable 351 
to block the p65 binding (lane 8, Fig.6D). The PDTC (NF-κB inhibitor) also eliminated binding (lane 9, vs. lane 4 or 352 
vs. lane 10, normoxia). These results strongly suggest that NF-κB binding at site p838 of the Crhr1 promoter plays a 353 
key role in transcriptional activation of CRHR1 expression by hypoxia.  354 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 17
 355 
3.7 Transcription factor Jun/AP-1 and NF-κB binds at the region of the CRHR1 promoter   356 
 357 
Bioinformatics analysis predicts that there are twelve Jun/AP-1 and twelve NF-κB binding sites in the 5’ flanking 358 
region of mouse CRHR1 gene, between -2700 and +1 (Supplementary, Fig.1), and eleven Jun/AP-1 and six NF-κB 359 
binding sites in the 5’ flanking region of rat CRHR1 gene, between -2700 and +1” (Supplementary Fig. 2). We have 360 
identified  five Jun/AP-1 and eight NF-κB binding sites in the 5’ flanking region of mouse CRHR1 gene by CHIP-361 
PCR in AtT-20 cells (Supplementary Fig. 4, original bands). In normoxia, CRH treatment induced an increased 362 
binding at the region of the CRHR1 promoter (representative bands for AP-1 binding site 1, AP-1-1) and NF-κB 363 
binding site 1, NF-κB-1), the increased binding can be decreased by the inhibitor of AP-1(SR11302) or NF-κB 364 
(PDTC) respectively (Fig.7A, B), under hypoxia, the increased binding can be blocked by the inhibitor of AP-1 or 365 
NF-κB respectively. CRH induced-increased transcription of the CRHR1 promoter markedly blocked after 366 
incubation with the inhibitor of AP-1 or NF-κB (Fig.7C, D) in normoxia and hypoxia respectively. 367 
 368 
4. Discussion 369 
 370 
We have reported that hypobaric hypoxia causes an activation of the HPA axis and stimulates the brain-371 
neuroendocrine-immune network systems, leading to physiological dysfunction and consequent behavioral 372 
abnormality as well as acute mountain sickness in which CRH and its CRHR1 play a crucial role (Chen et al., 2012; 373 
Fan et al., 2009; Fan et al., 2013; Wang et al., 2013; Wang et al., 2004; Xu et al., 2006; Chen et al., 2014; Song et al., 374 
2016). The pituitary is the major component of the HPA axis, delivering central neuroendocrine regulation in a 375 
manner determined, in great part, by CRH release and CRHR1 expression at the level of the hypothalamus and 376 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 18
pituitary (Chen et al., 2012; Fan et al., 2009; Fan et al., 2013; Wang et al., 2013; Wang et al., 2004; Xu et al., 2006; 377 
Chen et al., 2014; Pournajafi-Nazarloo et al., 2011). Although CRHR1 mRNA changes by hypoxia have been shown 378 
in the pituitary (Wang et al., 2004) the cellular and molecular mechanisms involved have not been addressed. The 379 
present study reveals that hypoxia induces an initial fast decrease of CRHR1 mRNA expression in the pituitary that 380 
is followed by a delayed increase in expression. This is associated with negative transcriptional control of CRHR1 381 
promoter by CRHR1 triggered signaling and transcriptional factor AP-1 as well as positive transcriptional activation 382 
by NF-κB, and HIF-1α respectively (Fig.8). 383 
      Increasing evidence suggests that stress alters the methylation status of CRH and/or CRHR1 DNA in the brain 384 
and that this is associated with both changes in CRHR1 mRNA expression and behavioral dysfunction (Wang et al., 385 
2013; Wang et al., 2014; Sotnikov et al., 2014; Elliott et al., 2010; Mueller and Bale, 2008; Jaenisch and Bird, 2003; 386 
de Kloet et al., 2005). Importantly, methylation is known to repress gene transcription by blocking the binding of 387 
transcription factors to double-stranded DNA (Kass et al., 1997). Early life stress, such as postnatal maternal 388 
separation, increases hippocampal CRH expression, while blockade of CRHR1 signaling ameliorates the 389 
hippocampal synaptic dysfunction and memory defects that accompany decreased methylation of the CRH promoter 390 
(Wang et al., 2014). Epigenetic regulation of CRHR1 expression plays a critical role in trait anxiety, with 391 
bidirectional changes in its expression in the basolateral amygdala having been noted in response to environmental 392 
cues and linked to increased methylation status of the CRHR1 promoter (Sotnikov et al., 2014). We have previously 393 
reported that gestational hypoxia induced a decrease in CRHR1 promoter methylation within CpG island region in 394 
the hypothalamus, which was associated with gender-biased anxiety-like behavior in male offspring (Wang et al., 395 
2013). A short exposure of gestational dams to hypoxia (SGH) decreased the levels of DNA methylation at specific 396 
CpG sites (-535) within the CRHR1 promoter in the hypothalamus of E19 embryos (Wang et al., 2013), whilst there 397 
was increased CRHR1 protein and mRNA expression, suggesting that decrease of DNA methylation of CRHR1 398 
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seems to be associated with positive CRHR1 transcription in the hypothalamus of E19 embryos (Wang et al., 2013). 399 
However, the methylation levels of the CRHR1 promoter in pituitary of the male offspring appear to be not 400 
associated with CRHR1 mRNA expression, because the methylation at specific CpG sites (-547,-544, -535) of the 401 
CRHR1 promoter was decreased in P1 male pituitary and no change in P7, P14, and P21 male offspring (Fig. 1A,B), 402 
but CRHR1 mRNA expression was also decreased in P1 and P14 pituitary. This non-causality may be associated 403 
with a lower response pattern during the early developmental period of neonatal offspring, as the baseline of Corts is 404 
lower in P2-P12 pups (Chintamaneni et al., 2013).  Exposure of P8 rat to hypoxia (8% inspired O2 for 4 h) resulted 405 
in a decrease CRHR1 mRNA expression in anterior pituitary (Bruder et al., 2008), which seems to be similar to the 406 
SGH induced changes in our offspring (Fig.1). Surprisingly, CRHR1 mRNA expression was significantly decreased 407 
in P1 and P14 pituitary of all offspring exposed to SGH, but was dramatically increased in pituitary of P21 offspring 408 
under both normoxia and hypoxia (Fig. 1A). This is likely associated with offspring isolation from the mother 409 
during weaning, feeding and metabolic demands of body development, and the new environment at P21. In this 410 
respect it is notable that reduced methylation of the CRHR1 promoter in the PVN is likely associated with both 411 
increased CRHR1 expression and anxiety-like behavior in P90 male offspring following exposure to gestational 412 
hypoxia (Wang et al., 2013). By contrast, no such association was observed with respect to the methylation status of 413 
CRHR1 promoter in the pituitary at early period of neonatal developing of offspring rats. This change of CRHR1 414 
DNA methylation in offspring pituitary seems not be associated with the development of anxiety-like behavior 415 
because of maternal protective effect for fetus. 416 
Hypoxia in tissues or cells occurs during a diverse array of diseases, including inflammation, cancer disease 417 
(Rocha, 2007; Cummins and Taylor, 2005; Seta and Millhorn, 2004; Bruning,2012) and acute mountain sickness 418 
(Chen et al., 2014; Song et al., 2016; Hao et al., 2015). Gene array analysis has revealed global changes in the 419 
transcriptome during hypoxia. A cohort of alternatively regulated genes, including those for the glucocorticoid 420 
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receptor (GR) and transcription factors CREB, AP-1, HIF-1α, NF-κB, may therefore contribute to hypoxia-induced 421 
changes in transcriptional activity and cell phenotype that are both cell-type and cell-stage specific (Rocha, 2007; 422 
Cummins and Taylor, 2005; Stem et al., 2011; Bandyopadhyay et al., 1995). HIF-1α activity was induced during the 423 
early phase of hypoxia, while NF-κB was activated during the later phase, and synergistic behaviour of HIF and NF-424 
κB during hypoxic inflammation (Bruning et al., 2012; Nakayama, 2013; Walmsley et al., 2005). In the present 425 
study, we showed that exposure of the adult rat pituitary to a short hypoxia induced a fast phase of suppressed 426 
CRHR1 mRNA expression which was switched to an increase when exposed to a prolonged hypoxia, this biphasic 427 
effect involved CRHR1 signaling and NF-κB as it could be blocked by a CRHR1 antagonist and an NF-κB inhibitor, 428 
respectively (Fig. 2). Since local CRH mRNA expression was simultaneously increased in the pituitary via NF-κB 429 
(Fig. 2G) and CRHR1 signaling-activated transcription of CRH promoter (Fig.2H), which is supported by cAMP-430 
PKA activated CREB of CRH promoter (Kageyama and Suda, 2010), thereby CRH might also be involved in the 431 
fast suppression of CRHR1 mRNA expression in the pituitary. Activating CRH causes a positive feedback control of 432 
CRHR1 promoter activity via PKA and PKC pathway in a primary culture of human pregnant myometrial cells 433 
(Parham et al., 2004). This distinct effect may be due to a tissue and cell specificity and stressor used. Given that 434 
hypoxia-activated local changes in CRHR1 expression and pituitary activities, an autocrine and/ or paracrine 435 
pathways, likely deliver changes in CRHR1 gene transcription events through CRHR1-signaling CREB, the cyclic 436 
AMP response element binding protein, through PKA or Calmodulin (CaM) kinase (Mayr and Montmin, 2001) and 437 
NF-κB action. Our proposal gains support from the findings that hypoxia induced activation of both Jun/AP-1 and 438 
NF-κB in pituitary by EMSA test and CHIP-PCR.  439 
To determine the mechanisms underpinning changes in CRHR1 gene expression by Jun/AP-1, NF-κB, and HIF-440 
1α, a series of truncated pGL3-basic plasmids that excluded the binding sites for these transcription factors were 441 
constructed and transfected into AtT20 cells, and their transcriptional activity was tested. We found that 1% hypoxia 442 
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activated the transcriptional activity of CRHR1 promoter (the length of p2161Luc) in AtT20 and primary rat 443 
pituitary cells, and that activity increased in a time-dependent manner over 24 h (Fig. 3). Besides the transcription 444 
activity of p2161Luc was dramatically enhanced after the three Jun/AP-1 binding sites were deleted, which shows 445 
that AP-1 acts to suppress CRHR1 transcription under normoxia and hypoxia. Furthermore, when deletion of the 446 
adjacent three HIF-1α (including HAS) binding sites dramatically reduced transcription activity in p838Luc of 447 
CRHR1 promoter under normoxia and hypoxia (Fig. 4B, p<0.001), suggesting that HIF-1α mediates activation of 448 
CRHR1 transcription. Deletion of the last HIF-1α site alone resulted in loss of any transcription of CRHR1 449 
promoter at p687Luc during hypoxia (Fig. 4B, p<0.001), which is consistent with NF-κB acting as a positive 450 
regulator of CRHR1 transcription. In addition, NF-κB mediated regulation of DNA-binding affinity in pituitary 451 
POMC gene by CRH (Karalis et al., 2004), while in AtT-20 cells CRH increases in AP-1-DNA (Autelitano and 452 
Cohen, 1996). Therefore, by differential regulation of the activity of NF-κB and AP-1, CRH may act in a classic 453 
physiological feedback loop to exquisitely regulate its own expression and that of CRHR1 in order to appropriately 454 
tune the response of the HPA axis. 455 
 456 
5. Conclusion 457 
In summary (Fig. 8), this study revealed that hypoxia-induced multimodal expression of rat CRHR1 gene in 458 
pituitary cells, is through local activation of CRH by autocrine and/or paracrine mechanisms. This occurs via the 459 
integration of signals carried by multiple transcription factors with Corts (via GR), and the Jun/AP-1 presenting 460 
negative control and with HIF-1α and NF-κB providing positive control. Therefore, the present study provides a 461 
novel insight into the molecular mechanisms of CRHR1 transcriptional control by hypoxia. 462 
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 595 
Figs 1-8 and Figure legend 596 
Fig. 1. CRHR1 mRNA expression and promoter methylation changes in pituitary (P1-P90) of SGH-treated male rat 597 
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offspring. A CRHR1 mRNA expression in P1 and P14 pituitary. B Alterations in DNA methylation of CRHR1 598 
promoter in P1-P21 pituitary. C CRHR1 mRNA expression in P90 pituitary. D Alterations in DNA methylation of 599 
CRHR1 promoter in P90 pituitary. All data are presented as means±SD. n=8-10, *p<0.05 vs. control 600 
 601 
Fig. 2. Hypoxia induced a bidirectional regulation of CRHR1 mRNA expression in adult male rat pituitary, and 602 
involvement of NF-κB and CRHR1 pathway. A Short hypoxia (SH, 8.2 % O2, 1 or 8 h) decreased CRHR1 mRNA 603 
expression ,*p<0.05, ***p<0.001 vs. control(Con), ###p<0.001 vs. 8 h. B Prolonged hypoxia (PH,10.8% O2 , 4 h/d,  604 
2 or 5 d) increased CRHR1 mRNA expression,  *p<0.05, ***p<0.001 vs. Con, ##p<0.01 vs. 2d. C, D SH(8.2 % O2, 605 
8 h)-decreased CRHR1 mRNA was not reversed by PDTC treatment(c),  but reversed by CRHR1 antagonist (CP 606 
154,526) treatment (D) *p<0.05, ***p<0.001, vs. hypoxia(-), #p<0.05, hypoxia+CP154,526 vs. hypoxia. E PH 607 
(10.8% O2, 4h/d, 5d) increased-CRHR1 mRNA was reversed by PDTC treatment, ***p<0.001, vs. hypoxia(-), 608 
###p<0.001, hypoxia+PDTC vs. hypoxia. F SH (8.2% O2, 8h) increased CRH mRNA expression in pituitary, 609 
*p<0.05, **p<0.01,***p<0.001, vs. Con, ###p<0.001, vs. hypoxia 2h and 24h. G, H SH increased-CRH mRNA was 610 
blocked by PDTC (G), and partly blocked by CRHR1 antagonist (CP154,526) (H), **p<0.01, ***p<0.001, vs. 611 
hypoxia(-) ; #p<0.05, hypoxia+PDTC, vs. hypoxia;  I PH (10.8% O2, 4h/d, 2d ) increased-CRHR1 mRNA was not 612 
reversed by Dex treatment. J SH enhanced plasma corticosterone levels, **p<0.01,***p<0.001, vs.   its own control, 613 
respectively, mean±SD,  n=7 in each group. K, L Hypoxia induced NF-κB binding affinity tested by EMSA in rat 614 
pituitary. PH (10.8% O2, 4h/d, 5 d) increased p65 or p50 protein expression (Fig. 2 k, lane 3 vs.  2), which was 615 
abolished by Mut NF-κB (Fig.2 k, lane7 vs. 6) and partly by PDTC (Fig. 2 l, lane 3 vs. 1) (N=3-4 in each group). 616 
(NN= Non-relative probe; NA= Non-relative antibody; Competitor=NF-κB competitor; Antibody=p65/p50 antibody) 617 
 618 
Fig. 3. Hypoxia increased rat CRHR1 promoter activity in RPC and AtT20 cells. Cells co-transfected with 1µg 619 
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p2161Luc (the length of CRHR1 promoter) and pRL-TK plasmids and pRL-TK plasmids (empty vector pGL3-basic, 620 
as a control) respectively. A Hypoxia (1% O2) increased transcription of the rat CRHR1 gene in cultured PRC cells. 621 
B Hypoxia (1% O2) increased CRHR1 transcription in AtT20 cell. C Hypoxia (1% O2) time-dependently increased 622 
Transcription of CRHR1 promoter (p2161Luc) in AtT20 cell. All data are presented as means±SD. n=3-4 in each 623 
group, *p<0.05, ***p<0.001, vs.  normoxia control (21% O2) at the time point indicated. 624 
 625 
Fig. 4. Transcriptional factors, HIF-1α, NF-κB, and AP-1 were involved in the hypoxia-induced CRHR1 promoter 626 
activation. A Predicted binding sites distribution of hypoxia responsive cis-regulatory element in rat CRHR1 627 
promoter region, including four NF-κB (rectangle), five Jun /AP-1(triangle), eight HIF-1α (vertical line) binding 628 
sites, and one HAS(circle) as indicated in the 5’ flanking region from -2161 to +360. B A series of deletion 629 
(truncated reporter) constructs were generated according to the predicted distribution of the transcriptional factors at 630 
CRHR1 promoter region and comparison of those transcriptional activities of p2161Luc, p1218Luc, and p360Luc 631 
were taken respectively. Under both hypoxia and normoxia, the transcription activity of p1218Luc was higher than 632 
that of p2161Luc and p838Luc, due to AP-1 inhibitory effect on transcription activation by HIF-1α. The p838Luc 633 
showed a lower transcription. Most shortened p360Luc had no transcriptional activity. All data were compared 634 
between normoxia and hypoxia as well as among p2161Luc, p1218Luc, and p360Luc. All data are presented as 635 
means±SD. n=3-4 for each group, *p<0.05, **p<0.01, ***p<0.001, between normoxia and hypoxia, respectively, 636 
and +++p<0.001, p1218Luc vs. p2161Luc or p1218Luc vs. p838Luc. C Hypoxia (1% O2)-time course (1 to 24 h)-637 
dependent increase in the transcriptional activity among p2161Luc, p1289Luc, and Luc p838Luc of CRHR1 gene in 638 
AtT20 cell, ++p<0.01, +++p<0.001, for p1289Luc between normoxia and hypoxia (two black line); **p<0.01, 639 
***p<0.001, for p2161Luc between normoxia and hypoxia (two red line); ##p<0.01, for p838Luc between normoxia 640 
and hypoxia (two blue line).  641 
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 642 
Fig. 5. Transcriptional factor AP-1 was involved in hypoxia-reduced CRHR1 transcription. The transcriptional 643 
activity measured in cultured AtT20 cell transfected with p2161Luc, p1218Luc, and p838Luc respectively under 644 
normoxia or hypoxia. A The transcriptional activity of p2161Luc, p1218Luc, and p838Luc. The data are presented 645 
as means±SD, ***p<0.001, hypoxia vs. normoxia; ###p<0.001, p1218Luc vs. p2161Luc and p838Luc during 646 
normoxia, +++p<0.001, p1218 vs. p2161 or p838 during hypoxia. B CRH used in AtT20 cell to mimic CRH release 647 
under normaxia or hypoxia in intact rats. CRH (10 nM) induced a decreased CRHR1 mRNA during normoxia 648 
(21%O2) (**p<0.0 1, CRH vs. CRH (-), and this effect was reversed by AP-1 inhibitor (SR11302, 1 µM) (++p<0.01, 649 
CRH vs. CRH+AP-1 inhibitor).  1% O2 hypoxia enhanced CRHR1 mRNA (**p<0.0 1, vs. normoxia control (CRH 650 
(-), CRH (10 nM) could further increase hypoxia-increased CRHR1 mRNA (##p<0.01, CRH+1% O2 vs. 1% O2  + 651 
CRH (-), and this could not be abolished by AP-1 inhibitor (@@p<0.01, AP-1 inhibitor vs. CRH+AP-1 inhibitor). C 652 
EMSA experiments showed hypoxia increased Jun (AP-1) expression (lane 1 and 3, vs. normoxia lane 2 and 4. 653 
Mutation of AP-1 resulted in loss of Jun (AP-1) binding band (lane 5). Unlabeled probe (competitor of AP-1, lane 6) 654 
markedly displaced the binding band. Jun(AP-1) antibody eliminated the binding (lane 7), but non relative antibody 655 
(NA, lane 8) has no such effect. All data are presented as means±SD. n=3-4 in each group. 656 
 657 
Fig. 6. NF-κB (binding site 838) was involved in increased transcription of CRHR1 gene during hypoxia. The 658 
transcriptional activity measured in cultured AtT20 cell transfected with p838Luc or mutated p838Luc, respectively 659 
during normoixa or hypoxia.  A Hypoxia (1% O2) increased transcriptions of p838Luc of CRHR1 promoter in AtT20 660 
cell, and the effect was abolished by PDTC or mutated NF-κB, **p<0.01, vs. hypoxia(-); ##p<0.01, hypoxia vs. 661 
PDTC+hypoxia. B Hypoxia activated transcription of p838Luc (NF-κB binding sites) , ***p<0.001, vs. normoxia at 662 
each time point indicated. C CRH (10 nM) decreased CRHR1 mRNA expression during normoxia, which was not 663 
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reversed by PDTC treatment, while  under hypoxia (1% O2) CRHR1 mRNA increased,  which was further increased 664 
by CRH (10 nM), and this effect was blocked by PDTC treatment, **p<0.01, ***p<0.001, vs. normoxia control 665 
(CRH(-); ++p<0.01, PDTC vs. PDTC+CRH; ##p<0.01, CRH  vs. CRH(-), @@p<0.01 CRH vs. CRH+PDTC. D 666 
EMSA was performed using nuclear extracts from AtT20 cells under 1% O2 hypoxia for 24 h. The sequences 667 
(CGGAGACTCC) specifically bind NF-κB. The p65 antibody was added into the binding reaction mixture with 668 
equal amount of AP-1 antibody used as a control. Lane 1, 2 and 3 as controls; lane 4: hypoxia induced p65 669 
expression that was abolished by NF-kB competitor (Lane 5), Mut NF-κB (Lane 6), NF-κB antibody (Lane 7), partly, 670 
non-relative antibody (NA) (Lane 8), and PDTC (lane 9), n=3-4 in each group. 671 
 672 
Fig. 7.  Transcription factor of AP-1 and NF-κB binds at the region of the CRHR1 promoter in AtT20 cell. A, B 673 
Inhibitor of AP-1 (A) or NF-κB (B) decreased or blocked the binding at the region of the CRHR1 promoter during 674 
normoxia (21%O2) and hypoxia (1%O2). C, D Inhibitor of AP-1(C) or NF-κB(D) blocked the transcription of the 675 
CRHR1 promoter during normoxia (21%O2) and hypoxia (1%O2). C, **p<0.0 1, CRH vs. CRH +inhibitor of AP-1 676 
under normoxia, #p<0.05, CRH vs. CRH+inhibitor of AP-1 under hypoxia. D, +p<0.0 1, CRH vs. CRH +inhibitor of 677 
NF-κB under normoxia, @p<0.05, CRH vs. CRH+inhibitor of NF-κB under hypoxia. DAPDH is included as an 678 
internal control, IgG is negative control. All data are presented as means±SD, n = 5 (Fig. C) and n = 8 (Fig. D). 679 
 680 
Fig. 8. Biphasic model of transcript of CRHR1 by Corts, Jun/AP-1, NF-κB, and HIF-1α during short and prolonged 681 
hypoxia in pituitary cell of adult rat.  682 
 683 
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Fig.5  b 的左边图太小，，加大些，但中间的柱子  0----150，可以变的窄一些。。。 
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Highlights 
CRHR1 mRNA response to hypoxia is spatio-temporal and developing stage dependent. 
Hypoxia induces a biphasic expression of CRHR1 mRNA in adult rat pituitary.   
c-Jun/AP-1 exerts a negative control at CRHR1 promoter,-p2161 to -p1289. 
 HIF-1α exerts a positive control at CRHR1 promoter,-p1218 to -p1140 and NF-κB,-p838. 
Integration of negative and positive input is required in CRHR1 transcription during hypoxia. 
 
 
